Moderna Plan to Test mRNA COVID and Flu Vaccines on 410,000 Elderly a ‘Catastrophe in the Making,’ Critic Says - Science, Public Health Policy and the Law
Article excerpt
Highlighted: the sentence this signal was extracted from
By Michael Nevradakis, Ph.D. Scientists and physicians critical of mRNA vaccines warn that a new clinical trial for Moderna's combination mRNA COVID-19 and flu vaccine could expose hundreds of thousands of older adults to serious health risks, including cardiac problems, blood clots and death. The warnings stem from concerns about adverse event data associated with the two vaccines used in the trial and the trial's methodology. The " DAN-COMBO " study will compare Moderna's mRNA-1083 combination shot with two separate shots: Moderna's Spikevax COVID-19 vaccine and its mRNA-1010 high-dose flu vaccine . The large-scale trial, which Moderna plans to conduct in Denmark and Spain, seeks to enroll 410,000 healthy Danish adults age 65 and older. It's scheduled to launch this month and run through next year's cold-and-flu season. The trial could involve up to one-third of Denmark's 65-and-over population, according to an analysis by the World Council for Health Scandinavia. According to the DAN-COMBO research team, the study is needed because "knowledge is still lacking" about the relative efficacy of a combination COVID-19 and flu vaccine compared with two standalone shots. But scientists and physicians critical of mRNA vaccines have warned that Moderna's new clinical trial could expose older adults to serious adverse events. Brian Hooker, Ph.D., chief scientific officer of...
Keep reading with a free account
The rest of this article, and every signal for Moderna, is in your free account.
